Adamas announces fda filing acceptance of snda to modify the indication statement for gocovri® to include treatment for parkinson’s disease patients receiving levodopa and experiencing off episo

Adamas announces fda filing acceptance of snda to modify the indication statement for gocovri® to include treatment for parkinson’s disease patients receiving levodopa and experiencing off episodes.adamas pharmaceuticals - anticipated pdufa action date is february 1, 2021 for gocovri snda.
ADMS Ratings Summary
ADMS Quant Ranking